
CLAIMS

1. A compound of formula (1)



(1)

or a pharmaceutically acceptable enantiomer, diastereomer, salt, or solvate thereof, wherein:

Ar is a 9- or 10-membered bicyclic aromatic ring system, where Ar is optionally substituted with one, two or three substituents;

L is selected from a direct bond and methylene;

R^1 is selected from hydrogen, halide, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_3-C_6cycloalkoxy and C_1-C_6alkoxy substituted with C_3-C_6cycloalkyl;

A is selected from a direct bond, $–CH_2–$ and $–CH_2CH_2–$;

E is selected from $–C(O)-R^2$, $C(OR^3)R^4R^5$ and $CH(R^6)NR^7R^8$;

R^2 is selected from methyl, ethyl and phenyl;

R^3 is selected from H, alkyl and substituted alkyl;

R^4 is selected from hydrogen, alkyl and phenyl;

R^5 is selected from C_1-C_7alkyl, C_1-C_7haloalkyl, phenyl and substituted phenyl;

R^6 is selected from hydrogen, methyl, halogenated methyl and ethyl;

R^7 is hydrogen; and R^8 is hydrogen, methyl or ethyl; with the proviso that together, R^7 and R^8 may form a 5 or 6-membered, optionally substituted, heterocycle.

2. The compound of claim 1 wherein

Ar is 1,3-benzothiazole optionally substituted with one substituent selected from halide, C_1-$_6$alkyl; -S-C_1-$_6$alkyl; -O-C_1-$_6$alkyl; and -SO_2-C_1-$_6$alkyl;

R^3 is H;

R^4 is selected from hydrogen, C_1-C_7alkyl and phenyl; R^5 is selected from C_1-C_7alkyl, C_1-C_7haloalkyl, phenyl and halophenyl; and

R^7 is hydrogen and R^8 is hydrogen, methyl or ethyl; or R^7 and R^8 together form a 5- or 6-membered heterocycle which is optionally substituted with a substituent selected from C_1-C_6alkyl and carboxylic acid.

3. The compound of claim 1 or claim 2, wherein Ar is substituted with a single substituent which is $–S-CH_3$.

4. The compound of any one of claims 1 to 3, wherein L is a direct bond.

5. The compound of any one of claims 1 to 4, wherein R^1 is hydrogen or C_1-C_6alkoxy.

6. The compound of any one of claims 1 to 5, wherein A is a direct bond.

7. The compound of any one of claims 1 to 6, wherein E is $-C(OR^3)R^4R^5$ and R^3 is H, and R^5 is trifluoromethyl.

8. The compound of any one of claims 1 to 7, as a non-racemic mixture of enantiomers of compounds of formula (1).

9. The compound of claim 1 selected from:

1-[4-(1,3-benzothiazol-2-yloxy)-3-methoxyphenyl]-3-(trifluoromethyl)pentan-3-ol;

1-{3-methoxy-4-[(4-methylsulfanyl-1,3-benzothiazol-2-yl)oxy]phenyl}-3-(trifluoromethyl)pentan-3-ol;

1-{4-[(4,6-difluoro-1,3-benzothiazol-2-yl)oxy]-3-methoxyphenyl}-3-(trifluoromethyl)pentan-3-ol;

1-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-3-methoxyphenyl}-3-(trifluoromethyl)pentan-3-ol;

4-[4-(1,3-benzothiazol-2-yloxy)-3-methoxyphenyl]-1,1,1-trifluoro-2-methylbutan-2-ol;

1,1,1-trifluoro-4-(3-methoxy-4-{[4-(methylsulfanyl)-1,3-benzothiazol-2-yl]oxy}phenyl)-2-methylbutan-2-ol;

1-(3-methoxy-4-{[4-(methylsulfanyl)-1,3-benzothiazol-2-yl]oxy}phenyl)pentan-3-ol; and

1-(4-{[4-(methylsulfanyl)-1,3-benzothiazol-2-yl]oxy}phenyl)-3-(trifluoromethyl)pentan-3-ol.

10. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable enantiomer, salt or solvate thereof, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.

11. The pharmaceutical composition of claim 10 in the form of an eyedrop.

12. Use of a compound of formula (1) in the manufacturing of a medicament for the treatment of an inflammatory disease or inflammatory condition, a respiratory disease or a neurodegenerative disease, condition or disorder.

13. The use of claim 12, wherein the inflammatory disease or inflammatory condition is an ocular inflammatory disease or an ocular inflammatory condition.

14. The use of claim 12, wherein the disease is a respiratory disease or condition.

15. The use of claim 12, wherein the disease is a neurodegenerative disease, condition or disorder.